RAAS Stock Sees 14.29% Price Target Hike to CN¥8.16 Per Share

Shanghai RAAS Blood Products Co. (SZSE:002252) is attracting renewed analyst attention as the consensus price target has been revised upward to CN¥8.16 per share, marking a significant 14.29% increase from the previous estimate of CN¥7.14 set in mid-January 2026. This repricing reflects strengthening confidence among equity research analysts covering the Shanghai-based blood products manufacturer.

Upside Potential of 30% From Current Trading Levels

The revised consensus price target represents a 30.14% premium over the latest closing price of CN¥6.27 per share, suggesting meaningful upside potential for investors at current levels. Analyst targets currently span a relatively tight range, with estimates clustering between CN¥8.08 on the low end and CN¥8.40 on the high end. This narrow band of forecasts indicates growing consensus among the analyst community regarding RAAS’s near-term valuation trajectory.

Modest Dividend Yield at 0.48% With Steady Payout Discipline

At present prices, Shanghai RAAS is delivering a dividend yield of 0.48%, coupled with a conservative payout ratio of 0.11. This metric indicates the company returns only 11% of earnings to shareholders via dividends while retaining 89% for reinvestment and operational needs. The company maintains a disciplined capital allocation approach consistent with firms in growth mode, retaining substantial earnings to fund expansion initiatives. Over the past three years, RAAS has demonstrated commitment to shareholders by growing its dividend at a 0.07% annual rate.

Institutional Positioning: 45 Funds Report Exposure to RAAS

The fund community shows meaningful exposure to Shanghai RAAS, with 45 institutions or funds currently maintaining disclosed positions in the company. However, this represents a notable pullback, with institutional ownership declining by 16 fund holders—a 26.23% decrease in fund count over the most recent quarter. Despite the reduction in participating funds, the average portfolio weight dedicated to RAAS among all holding funds increased to 0.04%, up 15.03% quarter-over-quarter. This divergence suggests that remaining holders are actually increasing their conviction. Total institutional share ownership has declined by 35.64% to 23,075K shares over the past three months.

Major Fund Movements in RAAS Holdings

Several major index funds and specialized sector ETFs are among the institutional holders of RAAS stock:

Vanguard Total International Stock Index Fund Investor Shares (VGTSX) commands the largest disclosed position with 6,089K shares representing 0.09% company ownership. The fund increased its holdings by 1.77% from the previous quarter but paradoxically reduced its RAAS portfolio allocation by 2.00%, reflecting overall fund growth outpacing RAAS share additions.

Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX) maintains a substantial 5,971K share position equivalent to 0.09% ownership with no change in holdings during the latest quarter.

KraneShares MSCI All China Health Care Index ETF (KURE), a specialized sector vehicle focusing on Chinese healthcare, holds 1,057K shares (0.02% ownership). The fund modestly increased its stake by 0.27% but trimmed its relative portfolio allocation in RAAS by 1.91%.

Dimensional Emerging Markets Value Fund represents the largest institutional seller, having cut its RAAS position by 26.71% to 1,039K shares representing 0.02% ownership. The fund reduced its portfolio allocation by 26.67%, signaling a deliberate reduction in exposure.

Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) increased its commitment to RAAS, raising holdings by 10.32% to 1,023K shares while expanding its portfolio allocation by 5.38%, demonstrating renewed interest from this broad international equity vehicle.

The mixed institutional activity—with some major funds trimming exposure while others increase positions—suggests a period of portfolio rebalancing rather than broad institutional retreat from the RAAS investment thesis.